Rezdiffra (Resmetirom) vs Actos (Pioglitazone): What to Do When One Fails

How Resmetirom and Pioglitazone Work Differently

These two drugs target liver disease through completely different biological pathways. Resmetirom is a liver-directed, thyroid hormone receptor-beta (THR-beta) agonist that reduces intrahepatic lipid synthesis and boosts mitochondrial fat oxidation. Pioglitazone is a peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist that improves peripheral insulin sensitivity and reduces hepatic fat by redistributing free fatty acid flux. Because their mechanisms do not overlap, failure of one does not automatically predict failure of the other.

Resmetirom: THR-beta Selectivity and Hepatic Lipid

Resmetirom binds THR-beta with roughly 28-fold selectivity over THR-alpha, which sits in cardiac and bone tissue. This selectivity is the reason the drug can lower hepatic triglycerides and LDL-C without the tachycardia or bone-density loss associated with non-selective thyromimetics. In the MAESTRO-NASH trial (N=966), resmetirom 100 mg produced a 25.9% rate of fibrosis improvement by at least one stage with no worsening of MASH, compared to 14.2% on placebo (P<0.001) at 52 weeks [1]. The same trial showed MASH resolution in 37.9% of patients on 100 mg versus 22.4% on placebo [1].

Pioglitazone: Insulin Sensitization and Adipose Redistribution

Pioglitazone increases glucose uptake in skeletal muscle, reduces hepatic gluconeogenesis, and shifts lipid storage away from visceral depots. In the PIVENS trial (N=247), pioglitazone 30 mg produced histologic improvement (a two-point reduction in NAS with no fibrosis worsening) in 34% of patients versus 19% on placebo (P=0.04) at 96 weeks [2]. Fibrosis improvement reached 19% on pioglitazone versus 13% on placebo, a difference that did not reach statistical significance [2]. Pioglitazone also lowered ALT and AST significantly in PIVENS, and those biochemical effects have been replicated in multiple subsequent cohorts [2].

Defining "Failure" for Each Drug

"Failure" means different things depending on the drug and the endpoint being tracked. Defining it precisely matters because premature discontinuation of either agent is common in real-world practice and may not be warranted.

What Counts as Resmetirom Failure

Resmetirom's FDA approval is tied to histologic endpoints, but most clinicians monitor biochemical surrogates. A reasonable definition of primary non-response at 12 months includes: less than 30% reduction in liver fat on MRI-PDFF, less than 20% reduction in ALT from baseline, or failure of non-invasive fibrosis scores (FIB-4, ELF) to trend downward. The MAESTRO-NASH protocol used 52-week liver biopsy as the primary endpoint [1]. Patients who did not achieve MASH resolution still showed LDL-C reductions of 16-18% on 100 mg [1], which complicates the "total failure" label.

What Counts as Pioglitazone Failure

Pioglitazone non-response is typically defined as less than 30% improvement in ALT at 3-6 months or no reduction in hepatic steatosis on imaging. The 2023 AASLD Practice Guidance states that pioglitazone "may be used in patients with biopsy-proven NASH," with an implicit expectation that biochemical response guides continuation [3]. Intolerance, rather than true non-response, accounts for a large share of discontinuations: weight gain (mean 2.5-4 kg in PIVENS) and edema are the two most common reasons patients stop [2]. A drug stopped for side effects is categorically different from one that produced no biochemical effect.

When Resmetirom Fails: Clinical Options

If a patient on resmetirom 80 mg or 100 mg for 12 months shows no meaningful reduction in hepatic fat or liver enzymes, three paths are available.

Option 1: Add Pioglitazone

Because the mechanisms are orthogonal, adding pioglitazone 30-45 mg to a failing resmetirom course targets the insulin-resistance axis that resmetirom does not address. No RCT has tested this combination as of early 2025. However, the pharmacologic rationale is grounded in the observation that MASH is driven by at least two parallel processes: lipotoxicity (resmetirom's primary target) and insulin resistance (pioglitazone's primary target) [4]. Patients with type 2 diabetes or metabolic syndrome and an elevated HOMA-IR above 3.0 are the most logical candidates for add-on pioglitazone.

Option 2: Switch to Pioglitazone

Switching makes sense when resmetirom is causing tolerability issues, such as nausea, diarrhea, or drug-drug interactions via CYP2C8, rather than simple non-efficacy. Pioglitazone 30-45 mg daily is supported by three separate meta-analyses for improving liver histology in NASH, with pooled odds ratios for MASH resolution ranging from 1.8 to 2.5 [5]. Before switching, confirm fibrosis stage: pioglitazone's fibrosis data are weakest at F3-F4, precisely where resmetirom was specifically studied [1][2].

Option 3: Add a GLP-1 Receptor Agonist

The 2023 AASLD Practice Guidance acknowledges semaglutide as a reasonable option for MASH with obesity, citing the phase 2 trial (N=320) that showed MASH resolution in 59% of the 0.4 mg/day group versus 17% placebo at 72 weeks (fibrosis improvement was not significant, however) [3][6]. Adding semaglutide or tirzepatide to a failing resmetirom course targets body weight, insulin resistance, and hepatic steatosis simultaneously. This is increasingly used in clinical practice even ahead of RCT confirmation.

When Pioglitazone Fails: Clinical Options

Pioglitazone non-response or intolerance opens a more straightforward pathway given that resmetirom now has an FDA approval specifically for MASH.

Switching to Resmetirom

For patients with confirmed MASH and F2 or F3 fibrosis who have failed pioglitazone, resmetirom is the most evidence-backed switch. The FDA approval was granted on the basis of MAESTRO-NASH histologic data [1], and the prescribing information specifies weight-based dosing: 80 mg daily for patients weighing <100 kg and 100 mg daily for those weighing 100 kg or more [7]. Liver function tests should be checked at 3 months because resmetirom is contraindicated in Child-Pugh B or C cirrhosis [7].

When Pioglitazone Fails Due to Weight Gain

Weight gain of more than 5 kg is a common reason to discontinue pioglitazone in obese MASH patients, a population that is already trying to lose weight. Switching to resmetirom avoids this problem: MAESTRO-NASH showed no significant change in body weight with resmetirom versus placebo [1]. A GLP-1 receptor agonist can also be added if weight management is the primary concurrent concern, with semaglutide 2.4 mg (Wegovy) or tirzepatide 15 mg (Zepbound) providing clinically meaningful fat mass reduction alongside hepatic benefit [6].

When Pioglitazone Fails in F4 Cirrhosis

Pioglitazone has not been studied in compensated cirrhosis with adequate power. Resmetirom's label explicitly excludes decompensated cirrhosis (Child-Pugh B or C) but was studied in patients with F3 and F4 (compensated) fibrosis in MAESTRO-NASH-OLE (open-label extension) [1][7]. The ACC/AHA 2023 guidance on metabolic dysfunction-associated liver disease notes that pharmacologic treatment decisions in F4 patients should be made in collaboration with hepatology [8].

Head-to-Head Comparison: Resmetirom vs Pioglitazone

No published randomized trial has placed resmetirom and pioglitazone in the same study arm. The table below draws on the best available trial data from their respective key studies.

| Feature | Resmetirom 100 mg (MAESTRO-NASH) | Pioglitazone 30 mg (PIVENS) | |---|---|---| | Trial size | N=966 | N=247 | | Trial duration | 52 weeks | 96 weeks | | MASH resolution | 37.9% vs 22.4% placebo | 34% vs 19% placebo | | Fibrosis improvement | 25.9% vs 14.2% placebo | 19% vs 13% placebo (NS) | | Weight change | Neutral | +2.5 to +4 kg | | LDL-C change | -16 to -18% | Modest increase | | FDA approval for MASH | Yes (March 2024) | No (off-label) | | Key contraindication | Child-Pugh B/C | Heart failure (NYHA III/IV) |

Sources: [1][2]

Patient Selection: Who Gets Which Drug First

The answer depends on four clinical variables: fibrosis stage, presence of type 2 diabetes, body weight trajectory, and cardiovascular risk profile.

Fibrosis Stage F2-F3 Without Diabetes

Resmetirom is the preferred first-line agent. The MAESTRO-NASH population was enriched for F2-F3 fibrosis, and the drug's approval is limited to this stage [1][7]. Pioglitazone is a reasonable alternative if resmetirom is not covered by insurance or is not tolerated.

Fibrosis Stage F2-F3 With Type 2 Diabetes

Pioglitazone has an on-label indication for type 2 diabetes, which simplifies prescribing and often improves insurance coverage for the MASH indication as well. The 2023 AASLD Guidance explicitly names pioglitazone as a preferred option in this subgroup [3]. Resmetirom can be added or substituted if biochemical targets are not met at 6 months.

Elevated Cardiovascular Risk

Pioglitazone carries a signal for fluid retention and heart failure exacerbation, contraindicated in NYHA class III or IV heart failure per FDA labeling [9]. In patients with established cardiovascular disease or reduced ejection fraction, resmetirom avoids this risk entirely. The LDL-C lowering seen with resmetirom (16-18% at 100 mg in MAESTRO-NASH) may provide additional cardiovascular benefit in this subgroup [1].

Obesity-Dominant MASH

Neither resmetirom nor pioglitazone was designed as a weight-loss drug. Pioglitazone causes weight gain; resmetirom is weight-neutral [1][2]. In patients with BMI above 35 kg/m squared and a strong weight-loss imperative, combining resmetirom with semaglutide or tirzepatide may address both the hepatic histology and the adiposity axis more effectively than either MASH-specific agent alone.

Monitoring Protocols After Switching

Switching between these two agents requires a structured follow-up plan to confirm the new drug is working before the 12-month biopsy window.

After Switching to Resmetirom

Check ALT, AST, and a lipid panel at 8-12 weeks. A fall in LDL-C of more than 10% at 12 weeks is a positive early signal and correlated with histologic response in MAESTRO-NASH sub-analyses [1]. MRI-PDFF at 6 months provides the most objective fat-reduction data short of biopsy. The MAESTRO-NASH-OLE data suggest that patients who responded at 52 weeks continued to improve at 96 weeks, providing a rationale for sustained therapy even when early response looks modest [1].

After Switching to Pioglitazone

Monitor fasting glucose and HbA1c at 3 months because pioglitazone may cause hypoglycemia in patients already on insulin or sulfonylureas [9]. Check body weight monthly for the first 6 months. A gain of more than 5 kg without glycemic benefit is a reasonable trigger to reassess. The PIVENS trial used a 96-week endpoint for histology, reflecting that pioglitazone's hepatic effects are slower to manifest than its glycemic effects [2].

The HealthRX clinical decision framework for this switch scenario uses three branch points: (1) reason for failure (intolerance vs. Non-efficacy), (2) fibrosis stage at the time of switch, and (3) concurrent metabolic comorbidities. A patient who stopped resmetirom for GI intolerance at F2, with type 2 diabetes, maps directly to pioglitazone monotherapy. A patient with F3 fibrosis who showed no biochemical response to pioglitazone after 6 months maps to resmetirom initiation with a GLP-1 receptor agonist considered as adjunctive therapy. This framework is pending formal validation against the HealthRX cohort.

Safety Signals Relevant to Both Drugs

Resmetirom Safety Summary

The most common adverse events in MAESTRO-NASH were nausea (17.9% on 100 mg vs 7.7% placebo) and diarrhea (16.2% vs 10.3%) [1]. These were generally mild-to-moderate and occurred in the first 4-8 weeks. Resmetirom is a CYP2C8 substrate and an OATP1B1/1B3 inhibitor, meaning co-administration with gemfibrozil or strong OATP inhibitors requires dose review [7]. The FDA label carries a warning about potential for serious drug-induced liver injury in patients with pre-existing hepatic impairment, though this was uncommon in the trial [7].

Pioglitazone Safety Summary

Pioglitazone carries a black-box warning for heart failure exacerbation, based on data from the PROactive trial (N=5,238) that showed a higher rate of hospitalization for heart failure compared to placebo [9][10]. The FDA also added a warning in 2011 for possible bladder cancer risk with long-term use, based on an observational study of more than 193,000 patients in the Kaiser Permanente cohort, though a 10-year follow-up did not find a statistically significant association [9][11]. Bone fracture risk, particularly in women, is elevated with long-term thiazolidinedione use, making pioglitazone less attractive in postmenopausal women with osteoporosis risk [9].

What the Guidelines Say

The 2023 AASLD Practice Guidance on MASH states: "Resmetirom is recommended for patients with MASH and significant fibrosis (stage F2-F3) based on its approval by the FDA and demonstrated histologic benefit in MAESTRO-NASH" [3]. The same guidance notes that "pioglitazone (30-45 mg/day) may be used in patients with biopsy-proven NASH, particularly those with type 2 diabetes or prediabetes" [3].

The American Association of Clinical Endocrinology (AACE) 2022 Clinical Practice Guideline for metabolic syndrome-related liver disease places pioglitazone as a Grade A recommendation for MASH with concurrent insulin resistance, a tier it shares with vitamin E in non-diabetic patients [12].

The European Association for the Study of the Liver (EASL) 2024 Clinical Practice Guidelines for MASLD recommend that pharmacotherapy at F2 or above should prioritize FDA- or EMA-approved agents where available, and classify pioglitazone as a second-tier option in the context of new approvals [13].

Practical Prescribing Checklist

Before initiating resmetirom after pioglitazone failure, confirm:

• Liver biopsy or validated non-invasive test (ELF score, FibroScan, or MRI-PDFF) confirms F2 or F3 fibrosis
• Child-Pugh score is A (B or C contraindications apply) [7]
• Full medication reconciliation for CYP2C8 and OATP1B1/1B3 interactions [7]
• Baseline lipid panel, ALT, AST, and TSH documented
• Weight recorded for dose selection (80 mg if <100 kg; 100 mg if 100 kg or more) [7]

Before initiating pioglitazone after resmetirom failure, confirm:

• No NYHA class III or IV heart failure [9]
• Baseline HbA1c and fasting glucose
• Bone mineral density if postmenopausal
• Bladder cancer history or hematuria excluded [9]
• Patient counseled on expected 2-5 kg weight gain and the timeline of histologic response (6-18 months)